Literature DB >> 24806270

[Diastolic heart failure].

R Wachter1.   

Abstract

BACKGROUND: Heart failure with preserved ejection fraction (i.e. diastolic heart failure) accounts for about half of heart failure cases. The aim of this review is to reflect current knowledge regarding the epidemiology, pathophysiology and treatment.
RESULTS: Diastolic heart failure patients are principally elderly and predominantly female. Numerous pathophysiological alterations in this disease have been shown and recent therapeutic recommendations include control of cardiovascular risk factors and symptoms. New therapeutic options, such as inhibition of late sodium current, aldosterone receptor blockade, combined inhibition of AT1 receptor and the enzyme neprilysin, and phosphodiesterase 5 inhibition are discussed in this review and ongoing clinical trials are also briefly presented.
CONCLUSION: Diastolic heart failure remains a cardiac disease which is difficult to treat; however, new study results allow a better definition of a population of patients who could benefit from specific therapies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24806270     DOI: 10.1007/s00108-013-3428-z

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  18 in total

1.  Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study.

Authors:  Marco Guazzi; Marco Vicenzi; Ross Arena; Maurizio D Guazzi
Journal:  Circulation       Date:  2011-06-27       Impact factor: 29.690

2.  Altered Na(+) currents in atrial fibrillation effects of ranolazine on arrhythmias and contractility in human atrial myocardium.

Authors:  Samuel Sossalla; Birte Kallmeyer; Stefan Wagner; Marek Mazur; Ulrike Maurer; Karl Toischer; Jan D Schmitto; Ralf Seipelt; Friedrich A Schöndube; Gerd Hasenfuss; Luiz Belardinelli; Lars S Maier
Journal:  J Am Coll Cardiol       Date:  2010-05-25       Impact factor: 24.094

3.  The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.

Authors:  Scott D Solomon; Michael Zile; Burkert Pieske; Adriaan Voors; Amil Shah; Elisabeth Kraigher-Krainer; Victor Shi; Toni Bransford; Madoka Takeuchi; Jianjian Gong; Martin Lefkowitz; Milton Packer; John J V McMurray
Journal:  Lancet       Date:  2012-08-26       Impact factor: 79.321

4.  The perindopril in elderly people with chronic heart failure (PEP-CHF) study.

Authors:  John G F Cleland; Michal Tendera; Jerzy Adamus; Nick Freemantle; Lech Polonski; Jacqueline Taylor
Journal:  Eur Heart J       Date:  2006-09-08       Impact factor: 29.983

5.  Outcome of heart failure with preserved ejection fraction in a population-based study.

Authors:  R Sacha Bhatia; Jack V Tu; Douglas S Lee; Peter C Austin; Jiming Fang; Annick Haouzi; Yanyan Gong; Peter P Liu
Journal:  N Engl J Med       Date:  2006-07-20       Impact factor: 91.245

6.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.

Authors:  Margaret M Redfield; Horng H Chen; Barry A Borlaug; Marc J Semigran; Kerry L Lee; Gregory Lewis; Martin M LeWinter; Jean L Rouleau; David A Bull; Douglas L Mann; Anita Deswal; Lynne W Stevenson; Michael M Givertz; Elizabeth O Ofili; Christopher M O'Connor; G Michael Felker; Steven R Goldsmith; Bradley A Bart; Steven E McNulty; Jenny C Ibarra; Grace Lin; Jae K Oh; Manesh R Patel; Raymond J Kim; Russell P Tracy; Eric J Velazquez; Kevin J Anstrom; Adrian F Hernandez; Alice M Mascette; Eugene Braunwald
Journal:  JAMA       Date:  2013-03-27       Impact factor: 56.272

7.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.

Authors:  Salim Yusuf; Marc A Pfeffer; Karl Swedberg; Christopher B Granger; Peter Held; John J V McMurray; Eric L Michelson; Bertil Olofsson; Jan Ostergren
Journal:  Lancet       Date:  2003-09-06       Impact factor: 79.321

Review 8.  What mechanisms underlie diastolic dysfunction in heart failure?

Authors:  David A Kass; Jean G F Bronzwaer; Walter J Paulus
Journal:  Circ Res       Date:  2004-06-25       Impact factor: 17.367

9.  Irbesartan in patients with heart failure and preserved ejection fraction.

Authors:  Barry M Massie; Peter E Carson; John J McMurray; Michel Komajda; Robert McKelvie; Michael R Zile; Susan Anderson; Mark Donovan; Erik Iverson; Christoph Staiger; Agata Ptaszynska
Journal:  N Engl J Med       Date:  2008-11-11       Impact factor: 91.245

10.  Blunted frequency-dependent upregulation of cardiac output is related to impaired relaxation in diastolic heart failure.

Authors:  Rolf Wachter; Stephan Schmidt-Schweda; Dirk Westermann; Heiner Post; Frank Edelmann; Mario Kasner; Claus Lüers; Paul Steendijk; Gerd Hasenfuss; Carsten Tschöpe; Burkert Pieske
Journal:  Eur Heart J       Date:  2009-12       Impact factor: 29.983

View more
  1 in total

Review 1.  The Role of Oxidative Stress in Cardiovascular Aging and Cardiovascular Diseases.

Authors:  Carmine Izzo; Paolo Vitillo; Paola Di Pietro; Valeria Visco; Andrea Strianese; Nicola Virtuoso; Michele Ciccarelli; Gennaro Galasso; Albino Carrizzo; Carmine Vecchione
Journal:  Life (Basel)       Date:  2021-01-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.